Proof to Practice: Bringing Real-World Evidence to HER2-positive and HER2-Low and Ultra-Low Breast Cancer Care
CME | 1.00 Credit
Turn Evidence Into Practice Healthcare professionals are invited to participate in our CME activity, Real-World Evidence in HER2-Positive and HER2-Low and Ultra-Low Breast Cancer Care. Explore emerging evidence, address clinical practice gaps, and gain actionable insights to support informed treatment decisions and improve patient care.
Start activity
Real-World Evidence Builds Routine Clinical Patterns in Early and Metastatic Breast Cancer
Across all HER2 Expression Levels
T-DM1 retains meaningful benefit in heavily pretreated, more complex real-world populations, supporting its role as a standard HER2 - targeted option
Click Here for Summary/Action
Tucatinib provides durable HER2+ mBC treatment persistence and meaningful rwTTD post - T-DXd for many with brain mets, multiple prior lines
Click Here for Summary/Action
Signals suggest earlier use of T-DXd may improve patient outcomes
This initiative has been supported by unrestricted educational grants from
Daiichi Sankyo, Inc. and AstraZeneca.
